Francine Durocher
Chercheuse universitaire
Axe Endocrinologie et néphrologie
Publications
View all-
article Ahmadi SA, Tranmer JE, Ritonja JA, Flaten L, Topouza DG, Duan QL, Durocher F, Aronson KJ, Bhatti P
DNA methylation of circadian genes and markers of cardiometabolic risk in female hospital workers: An exploratory study
Chronobiol Int 39 (5), 2022.
-
article Ritonja JA, Aronson KJ, Flaten L, Topouza DG, Duan QL, Durocher F, Tranmer JE, Bhatti P
Exploring the impact of night shift work on methylation of circadian genes
Epigenetics 17 (10), 2022.
-
article Ritonja JA, Aronson KJ, Leung M, Flaten L, Topouza DG, Duan QL, Durocher F, Tranmer JE, Bhatti P
Investigating the relationship between melatonin patterns and methylation in circadian genes among day shift and night shift workers
Occup Environ Med 2022.
Projects
- Deciphering breast cancer HER2-negativity with regard to HER2-targeted therapy, from 2016-07-01 to 2026-03-31
- Omega-3 fatty acids in the prevention of breast cancer: role of obesity-related markers in breast tissues, from 2018-10-01 to 2026-09-30
- L’AIMZ-938, un nouveau promédicament anticancéreux pour le traitement des cancers du sein humain réfractaires aux traitements actuels et exprimant le cytochrome P450 1A1, from 2021-10-01 to 2026-09-30
- The effect of cannabinoid receptors on breast cancer survival, from 2022-09-01 to 2025-08-31
- TBC1D9: therapeutic target of the aggressiveness of triple negative breast cancer, from 2023-03-01 to 2026-03-31
- Impact des marqueurs épigénétiques du tissu adipeux mammaire sur l'efficacité des traitements par inhibiteurs de l'aromatase chez les femmes atteintes d'un cancer du sein hormono-dépendant, from 2024-09-10 to 2025-08-31
- Effect of environmental contaminants and methylome of breast adipose tissue on aromatase inhibitor efficacy in breast cancer, from 2016-07-01 to 2025-03-31
- Deciphering the role of FGD5 during breast cancer progression, from 2021-05-01 to 2024-03-31
- Breast adipocyte hypertrophy: a novel biomarker to predict breast cancer survival, from 2022-01-01 to 2024-12-31
- Investigating TBC1D9 clinical relevance in combination with chemotherapeutic drugs in triple negative breast cancer, from 2023-06-21 to 2024-03-31